Xencor Doses First Patient in Phase 1 Study of XmAb20717 Dual Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

On July 12, 2018 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, reported that the first patient has been dosed in XmAb20717-01 (DUET-2), a Phase 1, first-in-human, clinical trial of XmAb20717, a bispecific antibody that simultaneously targets PD-1 and CTLA-4 immune checkpoints for the treatment of multiple advanced solid tumors (Press release, Xencor, JUL 12, 2018, View Source [SID1234527677]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Built on the scaffold of Xencor’s XmAb bispecific Fc domain, XmAb20717 is the most advanced candidate in our suite of tumor microenvironment activators," said Paul Foster, M.D., chief medical officer at Xencor. "The dual blockade of PD-1 and CTLA-4 with XmAb20717 may promote superior T cell activation and proliferation compared to anti-PD-1 alone, and we look forward to studying its safety, tolerability and therapeutic activity in clinical trials."

By the end of 2018, Xencor expects to file Investigational New Drug applications for two additional tumor microenvironment activators including XmAb23104, a PD-1 x ICOS bispecific antibody, as well as XmAb22841, a CTLA-4 x LAG-3 dual checkpoint inhibitor.

DUET-2 is a Phase 1 multiple-dose, dose-escalation study that will characterize the safety and tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary anti-tumor activity of intravenous administration of XmAb20717 in patients with selected advanced solid tumors. For more information about DUET-2 please visit to View Source (identifier: NCT03517488).